<DOC>
	<DOCNO>NCT01614691</DOCNO>
	<brief_summary>This study ass safety efficacy SPARC1203 deliver via nasal spray patient allergic rhinitis</brief_summary>
	<brief_title>Safety Efficacy SPARC1203 Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Male female patient age 18 65 year ( inclusive ) history seasonal allergic rhinitis positive skin prick test History presence perennial allergic rhinitis Upper low respiratory tract infection 2 week Visit 2 Significant pulmonary disease allergic rhinitis mild asthma control beta2agonists alone Immunizations vaccination within 4 week prior Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>